Source:http://linkedlifedata.com/resource/pubmed/id/15162468
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
2004-5-26
|
| pubmed:abstractText |
A member of the costimulatory molecule family, inducible costimulator (ICOS), is expressed on activated T cells and plays a critical role in their primary activation and cytokine production. ICOS is involved in different immune phenomena, such as Th1-mediated autoimmune disease and graft rejection. Although blockade of ICOS costimulation theoretically may protect grafts from rejection, a single dose of anti-ICOS antibody did not result in the prolongation of rat liver allograft survival. However, in this article, we report that anti-rat ICOS antibody markedly enhanced the immunosuppressive activity of a suboptimal dose of tacrolimus (FK506). After fully allogenic DA to LEW liver transplantation, recipients received a single injection of tacrolimus (1 mg/kg, intramuscularly) with or without anti-ICOS antibody (1 mg/kg, intravenously). Recipient survival was significantly prolonged in rats treated with both the antibody and suboptimal tacrolimus (median survival time 44 days vs. 28 days with tacrolimus alone, P <.01). The extent of cell infiltration into the graft was closely associated with prolongation of recipient survival. Our findings thus demonstrate that anti-ICOS antibody immunotherapy combined with suboptimal tacrolimus has a synergistic effect in preventing hepatic allograft rejection and that it may induce long-term graft acceptance intimately associated with a marked reduction of intragraft T lymphocyte infiltration.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Differentiation...,
http://linkedlifedata.com/resource/pubmed/chemical/Icos protein, rat,
http://linkedlifedata.com/resource/pubmed/chemical/Immunosuppressive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Inducible T-Cell Co-Stimulator...,
http://linkedlifedata.com/resource/pubmed/chemical/Tacrolimus
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
1527-6465
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
10
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
743-7
|
| pubmed:dateRevised |
2011-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:15162468-Animals,
pubmed-meshheading:15162468-Antibodies, Monoclonal,
pubmed-meshheading:15162468-Antigens, CD,
pubmed-meshheading:15162468-Antigens, Differentiation, T-Lymphocyte,
pubmed-meshheading:15162468-Dose-Response Relationship, Drug,
pubmed-meshheading:15162468-Drug Synergism,
pubmed-meshheading:15162468-Graft Rejection,
pubmed-meshheading:15162468-Graft Survival,
pubmed-meshheading:15162468-Immunohistochemistry,
pubmed-meshheading:15162468-Immunosuppressive Agents,
pubmed-meshheading:15162468-Inducible T-Cell Co-Stimulator Protein,
pubmed-meshheading:15162468-Injections, Intramuscular,
pubmed-meshheading:15162468-Liver,
pubmed-meshheading:15162468-Liver Transplantation,
pubmed-meshheading:15162468-Male,
pubmed-meshheading:15162468-Rats,
pubmed-meshheading:15162468-Rats, Inbred Lew,
pubmed-meshheading:15162468-Rats, Inbred Strains,
pubmed-meshheading:15162468-Staining and Labeling,
pubmed-meshheading:15162468-Survival Analysis,
pubmed-meshheading:15162468-Tacrolimus,
pubmed-meshheading:15162468-Transplantation, Homologous
|
| pubmed:year |
2004
|
| pubmed:articleTitle |
Significant enhancement by anti-ICOS antibody of suboptimal tacrolimus immunosuppression in rat liver transplantation.
|
| pubmed:affiliation |
Department of Innovative Surgery, National Research Institute for Child Health and Development, Tokyo, Japan.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|